Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 13/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CTSA | P10619 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13578162 | 0.94 | RORC (0.46) | RORCPPARGCTSA | |
| Trifluoroacetic Acid SCHEMBL4329929 | 0.88 | RORC (0.47) | RORCPPARGCTSA | |
| Trifluoroacetic Acid SCHEMBL4329948 | 0.87 | ATM (0.46) | RORCPPARGATMNPC1RAB9A | |
| Trifluoroacetic Acid SCHEMBL4324553 | 0.87 | ATM (0.46) | RORCPPARGATMNPC1RAB9A | |
| Trifluoroacetic Acid SCHEMBL4328508 | 0.84 | PDE2A (0.38) | RORCPPARGPDE2A | |
| Trifluoroacetic Acid SCHEMBL4341502 | 0.83 | CNR2 (0.48) | RORCPPARGATMNPC1RAB9A | |
| Trifluoroacetic Acid SCHEMBL4320255 | 0.82 | CASP3 (0.46) | RORCPPARGATMNPC1RAB9A | |
| Trifluoroacetic Acid SCHEMBL4330430 | 0.82 | CASP3 (0.46) | RORCPPARGATMNPC1RAB9A | |
| SCHEMBL13578164 | 0.82 | RORC (0.48) | RORCPPARGCTSA | |
| SCHEMBL4331255 | 0.81 | CNR2 (0.45) | RORCPPARGATMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | RORC 135/4885PPARG 103/4885ATM 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.